3Q 2025 Total Revenue of $134.2 Million, a 12$36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29$38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 2026 Positive, Statistically Significant Real-World Health Outcomes Demonstrated for ASCENIV™ Record ASCENIV Demand a ...